UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000027662
Receipt number R000031681
Scientific Title Clinical effects and mechanisms of bronchial thermoplasty for severe bronchial asthma
Date of disclosure of the study information 2017/06/07
Last modified on 2021/03/30 17:01:05

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Clinical effects and mechanisms of bronchial thermoplasty for severe bronchial asthma

Acronym

Clinical trial on bronchial thermoplasty in patients with severe bronchial asthma

Scientific Title

Clinical effects and mechanisms of bronchial thermoplasty for severe bronchial asthma

Scientific Title:Acronym

Clinical trial on bronchial thermoplasty in patients with severe bronchial asthma

Region

Japan


Condition

Condition

Bronchial asthma

Classification by specialty

Pneumology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the mechanisms and effects of bronchial thermoplasty on symptomatic improvement in subjects with severe bronchial asthma.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The mean change in Asthma Quality of Life Questionnaire score from baseline to after bronchial thermoplasty

Key secondary outcomes

The mean changes in the following parameters from baseline to after bronchial thermoplasty: 1) results of cardiopulmonary exercise testing, which include exercise time, peak Vo2, Borg scale, O2-pulse, VD/VT,VE/Vo2, VE/Vco2, delta FiO2, and ETCO2; 2) low frequency (LF) component, high frequency (HF) component, and LF/HF, which will be measured using heart rate variability during the day and at night alone; 3) Asthma Control Test score; 4) peak expiratory flow; 5) forced expiratory volume in one second (FEV1); 6) measurements of respiratory resistance and respiratory reactance, including R5, R20, R5-R20, and Fres; 7) results of the methacholine challenge test using the astograph methods, including Dmin and SGrs/Grs count; 8) the frequency of rescue drug (i.e., short-acting beta 2 agonist) use; and 9) frequency of clinical exacerbation of asthma, which requires steroid administration


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1)Severe uncontrolled bronchial asthma on high-dose inhaled corticosteroids, which is equivalent to 1000 or more micro g/day of beclomethasone dipropionate and long-acting beta 2 agonist
2)Ability to tolerate bronchoscopy and suitable for bronchial thermoplasty
3)Aged 18 years or older
4)Provided written informed consent to participate in the study

Key exclusion criteria

1)Malignant tumors
2)Severe heart disease
3)Severe hepatic failure
4)Severe renal failure (serum creatinine levels 2.0 or more mg/dl)
5)Current use of a body defibrillator, such as pacemaker or implantable cardioverter defibrillator
6)Active infectious disease
7)Exacerbation of asthma or change in the drug regimen to include oral corticosteroids in the past 14 days
8)Change in the maintenance drug therapy for bronchial asthma in the past 4 weeks
9)Less than 65% post-bronchodilator %FEV1
10)Uncontrolled sinusitis
11)Requirement for oral steroid that is equivalent to more than 10 mg/day of prednisone to control bronchial asthma
12)Past history of intubation or admission to the intensive care unit due to bronchial asthma in the past 24 months
13)Past history in the past 12 months as follows; i) 4 or more infections of the lower respiratory tract, or ii) 3 or more admissions due to respiratory symptoms
14)Has smoked in the past 12 months or has a smoking history of 10 or more pack-years
15)Has previously undergone bronchial thermoplasty
16)Pregnancy or potential pregnancy
17)Judged inadequate to participate in the study by their physicians

Target sample size

12


Research contact person

Name of lead principal investigator

1st name Keisuke
Middle name
Last name Miki

Organization

National Hospital Organization Osaka Toneyama Medical Center

Division name

Department of Respiratory medicine

Zip code

560-8552

Address

5-1-1 Toneyama, Toyonaka, Osaka, 560-8552, Japan

TEL

+81668532001

Email

miki.keisuke.pu@mail.hosp.go.jp


Public contact

Name of contact person

1st name Keisuke
Middle name
Last name Miki

Organization

National Hospital Organization Osaka Toneyama Medical Center

Division name

Department of Respiratory medicine

Zip code

560-8552

Address

5-1-1 Toneyama, Toyonaka, Osaka, 560-8552

TEL

+81668532001

Homepage URL


Email

miki.keisuke.pu@mail.hosp.go.jp


Sponsor or person

Institute

National Hospital Organization Osaka Toneyama Medical Center

Institute

Department

Personal name



Funding Source

Organization

Grant-in-Aid for Clinical Research from National Hospital Organization

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

National Hospital Organization Osaka Toneyama Medical Center

Address

5-1-1 Toneyama, Toyonaka, Osaka, 560-8552

Tel

+81668532001

Email

410-chiken@mail.hosp.go.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2017 Year 06 Month 07 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2017 Year 05 Month 19 Day

Date of IRB


Anticipated trial start date

2017 Year 06 Month 07 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

This study is performed as a prospective study to evaluate the mechanisms and effects of bronchial thermoplasty on symptomatic improvement in subjects with severe bronchial asthma.


Management information

Registered date

2017 Year 06 Month 06 Day

Last modified on

2021 Year 03 Month 30 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031681


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name